Loading
A phase 1/2 trial of BPX-501 dose 1 in acute lymphoblastic leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant is a phase 1/2 interventional study registered as NCT01744223 by Bellicum Pharmaceuticals, with 36 participants enrolled, started 2013-03 and due to reach its primary completion in 2019-10-09. Interventions recorded: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4 and SCT.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/